Percutaneous aortic valve replacement (TAVI) is a new treatment option for patients that are inoperable or present a high surgical risk. Some studies have shown that the stroke rate may be higher with TAVI than with medical treatment or surgical replacement. Embolic protection has been used successfully for the carotids, but there is not much<a href="https://solaci.org/en/2015/06/24/protavi-c-embolic-protection-during-tavi/" title="Read more" >...</a>
Original title: Clinical outcomes and safety of transfemoral aortic valve implantation under general versus local anesthesia: subanalysis of the French Aortic National CoreValve and Edwards 2 registry. Reference: Oguri A et al. CircCardiovascInterv. 2014; 7:602-610. Transcatheter aortic valve replacement (TAVI) performed under local anesthesia is becoming an increasingly common procedure. This study compared clinical outcomes in patients<a href="https://solaci.org/en/2014/11/12/transfemoral-tavi-under-local-anesthesia-with-similar-results-to-general-anesthesia/" title="Read more" >...</a>
Original title: Comparison of Transfemoral TranscatheterAortic Valve Replacement Performedin the Catheterization Laboratory(Minimalist Approach) Versus HybridOperating Room (Standard Approach). Outcomes and CostAnalysis. Reference: VasilisBabaliaros et al. J Am CollCardiolIntv 2014;7:898–904. This retrospective study of a center analyzed the results of percutaneous aortic valve replacement (TAVR) performed with a minimally invasive technique that included the closure of the femoral access<a href="https://solaci.org/en/2014/08/25/tavr-minimally-invasive-shorter-hospital-stay-and-costs-without-compromising-safety-or-efficacy/" title="Read more" >...</a>
Original title: Early Regression of Severe Left Ventricular Hypertrophy After Transcatheter Aortic Valve Replacement Is Associated with Decreased Hospitalization. Reference: Brian Lindman, et al. JACC Cardiovasc Interv 2014;7:662-73. Left ventricular hypertrophy, defined by the increase of left ventricular mass, has long been associated to increased morbi-mortality in the context of different heart conditions. LV hypertrophy regression might<a href="https://solaci.org/en/2014/08/05/tavr-regression-of-left-ventricular-hypertrophy-decreases-re-hospitalization/" title="Read more" >...</a>
Original title: Factors associated with vascular complications in patients undergoing balloon-expandable transfemoral transcatheter aortic valve replacement via open versus percutaneous approaches. Reference: Kadakia MB et al. Circ Cardiovasc Interv. 2014; Epub ahead of print. This retrospective study included 331 patients undergoing transfemoral TAVR in one center between 2007 and 2013. 64% of the population were treated with<a href="https://solaci.org/en/2014/07/28/fully-percutaneous-vs-surgical-transfemoral-tavr-similar-major-vascular-complications-rate-and-shorter-hospital-stay/" title="Read more" >...</a>
Original title: The impact of live transmition on patients outcomes during transcatheter aortic valve replacement: Results fron the VERITAS study. Reference: Ron Waskman, et al. Cardiovascular Revascularization Medicine 2014;15:63-68 With the advancement of medical technology and the great development of telecommunications, performing live or edited cases has become a common occurrence in medical education, but one of<a href="https://solaci.org/en/2014/04/11/tvar-live-edited-broadcasts-are-safe/" title="Read more" >...</a>
Original title: Comparison of Two Antiplatelet Therapy Strategies in Patients Undergoing Transcatheter Aortic Valve Implantation. Reference: Eric Durand et al. Am J Cardiol 2013, et al. Percutaneous aortic valve replacement has been shown to be superior to medical treatment in inoperable patients and not inferior to surgery in high-risk patients. Anti-platelet therapy in these patients is usually<a href="https://solaci.org/en/2013/11/08/looking-for-the-best-anti-aggregation-scheme-after-tavi/" title="Read more" >...</a>
Original title: Post-Procedural Hypertension Following Transcatheter Aortic Valve Implantation Incidence and Clinical Significance. Reference: Gidon Y. Perlman et al. J Am Coll Cardiol Intv 2013. Article in press. Pre-procedural hypertension (HTN) is a risk factor and a predictor of increased mortality after surgical aortic valve replacement (AVR). The disappearance of the pressure gradient across the aortic valve following<a href="https://solaci.org/en/2013/05/02/post-tavi-hypertension-is-a-predictor-of-better-evolution/" title="Read more" >...</a>
Original title: 5-Year Outcome After Aortic Valve Implantation Reference: Stefan Toggweiler, et al. J Am Coll Cardiol 2013;61:413–9 Percutaneous aortic valve implantation (TAVI) is now a valid strategy as we know its short and medium term evolution but we do not have enough information available about the long term. The aim of this study was to analyze the<a href="https://solaci.org/en/2013/01/28/favorable-outcomes-at-5-years-post-tavi/" title="Read more" >...</a>
Original title: Incidence, Management and Outcomes of Cardiac Tamponade During Transcatheter Aortic Valve Implantation Reference: Ahmed Rezq et al. J Am Coll Cardiol Intv 2012;5:1264 –72 Transcatheter Aortic Valve Implantation (TAVI) for high risk patients is a valid strategy today but not without complications. Among these is cardiac tamponade, still rare but important because of its implication. There<a href="https://solaci.org/en/2013/01/23/tavi-and-cardiac-tamponade-a-rare-but-serious-complication/" title="Read more" >...</a>